Clinical Trial Goal
To find out:
- The highest dose of NX-1607 that's safe to give
- If NX-1607 is safe and works well to treat DLBCL
You may be able to join this trial if you:
- Are 18 years or older
- Have DLBCL or DLBCL with Richter's transformation
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with any of the following (your doctor can tell you this):
- Allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Autologous (your own cells) BMT in the last 3 months
- Anti-PD-1
- Anti-PD-L1
- CAR T-cell therapy in the last month
- Cytotoxic T-lymphocyte-associated protein 4 in the last month
- Hormonal therapy
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
NX-1607 is a small molecule inhibitor that blocks CBL-B in certain cells.
You’ll get:
You’ll get:
- NX-1607 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has not yet approved NX-1607.
Locations
Sponsors
lead: Nurix Therapeutics, Inc.
